Lenvatinib Mesylate | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Lenvatinib Mesylate
Health Canada Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Lenvatinib Mesylate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

21 API Suppliers, 10 USDMF, 5 EU WC, 3 KDMF, 6 NDC API, 13 Listed Suppliers

21 API Suppliers
10 USDMF
5 EU WC
3 KDMF
6 NDC API
13 Listed Suppliers

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

16 FDF Dossiers, 4 FDA Orange Book, 4 Europe, 8 Canada

16 FDF Dossiers
4 FDA Orange Book
4 Europe
8 Canada

DIGITAL CONTENT

9 NEWS #PharmaBuzz

9 NEWS #PharmaBuzz

MARKET PLACE

1 APIs

1 APIs

PATENTS & EXCLUSIVITIES

32 US Patents, 14 US Exclusivities, 16 Health Canada Patents

32 US Patents
14 US Exclusivities
16 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

16 All

01 12Eisai Limited

02 4Torys LLP

filter Patent Reset all filters

16 All

01 42426461

02 42543650

03 42652442

04 42771403

filter Product Reset all filters

16 All

01 16LENVATINIB MESYLATE

filter Dosage Reset all filters

16 All

01 16CAPSULE

filter Exp Date Reset all filters

16 All

01 42021-10-19

02 42024-12-22

03 42027-05-17

04 42030-08-16

Product Main Page

01

Eisai Limited

Lenvatinib Mesylate

BioAsia

Not Confirmed

Eisai Limited

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

Lenvatinib Mesylate

Brand Name : LENVIMA

Patent Number : 2652442

Filing Date : 2007-05-17

Strength per Unit : 10 mg (1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Eisai Limited

Lenvatinib Mesylate

BioAsia

Not Confirmed

Eisai Limited

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

Lenvatinib Mesylate

Brand Name : LENVIMA

Patent Number : 2543650

Filing Date : 2004-12-22

Strength per Unit : 10 mg (1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Torys LLP

Lenvatinib Mesylate

BioAsia

Not Confirmed

Torys LLP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2021-10-19

Date Granted : 2011-04-12

Lenvatinib Mesylate

Brand Name : LENVIMA

Patent Number : 2426461

Filing Date : 2001-10-19

Strength per Unit : 10 mg (1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2021-10-19

Date Granted : 2011-04-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Eisai Limited

Lenvatinib Mesylate

BioAsia

Not Confirmed

Eisai Limited

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-08-16

Date Granted : 2015-02-24

Lenvatinib Mesylate

Brand Name : LENVIMA

Patent Number : 2771403

Filing Date : 2010-08-16

Strength per Unit : 10 mg (1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2030-08-16

Date Granted : 2015-02-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Eisai Limited

Lenvatinib Mesylate

BioAsia

Not Confirmed

Eisai Limited

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

Lenvatinib Mesylate

Brand Name : LENVIMA

Patent Number : 2652442

Filing Date : 2007-05-17

Strength per Unit : 14 mg (1 x 4mg + 1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Eisai Limited

Lenvatinib Mesylate

BioAsia

Not Confirmed

Eisai Limited

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

Lenvatinib Mesylate

Brand Name : LENVIMA

Patent Number : 2543650

Filing Date : 2004-12-22

Strength per Unit : 14 mg (1 x 4mg + 1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

Torys LLP

Lenvatinib Mesylate

BioAsia

Not Confirmed

Torys LLP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2021-10-19

Date Granted : 2011-04-12

Lenvatinib Mesylate

Brand Name : LENVIMA

Patent Number : 2426461

Filing Date : 2001-10-19

Strength per Unit : 14 mg (1 x 4mg + 1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2021-10-19

Date Granted : 2011-04-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

08

Eisai Limited

Lenvatinib Mesylate

BioAsia

Not Confirmed

Eisai Limited

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-08-16

Date Granted : 2015-02-24

Lenvatinib Mesylate

Brand Name : LENVIMA

Patent Number : 2771403

Filing Date : 2010-08-16

Strength per Unit : 14 mg (1 x 4mg + 1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2030-08-16

Date Granted : 2015-02-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

09

Eisai Limited

Lenvatinib Mesylate

BioAsia

Not Confirmed

Eisai Limited

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

Lenvatinib Mesylate

Brand Name : LENVIMA

Patent Number : 2652442

Filing Date : 2007-05-17

Strength per Unit : 20 mg (2 x 10mg )

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

10

Eisai Limited

Lenvatinib Mesylate

BioAsia

Not Confirmed

Eisai Limited

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

Lenvatinib Mesylate

Brand Name : LENVIMA

Patent Number : 2543650

Filing Date : 2004-12-22

Strength per Unit : 20 mg (2 x 10mg )

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!